Love the analogy!
Nice to see you correct your own typos- I do the same! Saw 85,000 shares at the ask at 8.00 before and figured it was a MM ploy as well. Now it looks a bit more realistic. I think we hold 8.00 today.
Kutz- you are spot on. Once Arena is able to start selling Belviq on June 8th we will see a LOT of short covering and regained interest in ARNA. The same will occur with AMRN (albeit a bit more gradually due to the NCE and Anchor overhang). But in the end we will prevail. Note the low volume on both these days. AMRN gets immediately pounded every morning and then the shorts cover quickly because they don't want to get caught in the updraft. Hang in there buddy. We will do fine!
akanz2 is telling the truth and unitard (sp?) is just being obnoxious. I posted about the original WebMD post 2 weeks ago and also received another "WebMD Professional" post about Vascepa the other day as well. It is not spam. You have to sign up to receive information from WebMD and they send information that you can read or simply discard. This time it was for "professional" use and that certainly includes PA's Certified N.P.'s, as well as MD's.
Truer words were never spoken Swalchie!
You beat me to the punch this time. Got it today as well. This sort of marketing program is really smart. First Medscape last week now WebMD. The next phase will be TV commercials on FOX and CNN since the demographic is mostly people with ICD's and Diabetes.
I guess you didn't read my entire post. It was meant to be a bit amusing. But geez, the price just dropped 10 cents in 2 minutes. Getting frustrated again by these games. Guess the FDA didn't make any decision again this month in the OB.
I am going to buy about 70,000 Powerball tickets ( It's 600 million now and rising!). Wish me luck. If I do get crazy enough to do that you know AMRN will announce a buyout over the weekend for 35 dollars (and I will still lose the Powerball #$%$ shoot).
Laphroaig and Yamazaki 18 year olds are joining my crystal balls tonight (in separate glasses though).
But which year? lol!
Hmmm, always interesting when a large capital firm meets with a fledgling biotech. Lazard is meeting in London with ISRG the same day (today). Now all we have to do is get AMRN to a similar price as ISRG (or even 1/20th of ISRG!).
Me too.
My friend already has an order for the Tesla Model S. I was thinking of buying TSLA stock about 2 weeks ago when it was around 50 since I fully expected a huge short squeeze and decent earnings. It happened! But I didn't buy the stock- What a dummy I was. I need to trust my instincts (especially since my friend who ordered that car is a super techie and knows all about the company and Elon). I should have simply bought the stock after the IPO came out and it sank to around 21. That would have been the very smart thing to do. Oh well, so much for hindsight!
Hi Choubix- Are you referring to the June options which are now trading in only dollar increments? In general the option prices have been set at dollar intervals on a monthly basis over the past year but early in the month when the price moves appear to settle somewhere in between the dollar strikes you see the 50 cent increment options suddenly appearing (especially the 6.50, 7.50 and 8.50 ones). I noticed this last month when out of the blue the 50 cent increments appeared one day since the MM's determined there was an interest in those price points. You will probably see the half point strikes develop for the June options once the May options expire in 2 more days. Hope that helps! I just want it to stay above 7.00 by Friday!
It just continues torture me (and every other long here) after a nice little run up these past few days. Is Jody Arias shorting it?
Hope that was a typo! Methinks you actually meant "Sentiment"!
It certainly looks that way! Unless some shorts got scared and suddenly covered.
was surprised to see a detailed interactive discussion on a new treatment for dyslipidemia. so you get to learn all about Vascepa, it's efficacy, minimal side effect profile and how to incorporate it into your practice. It then had 4 case studies to show when and where Vascepa would prove effective at reducing hypertriglyceridemia and also detailed why simple OTC Omega-3's are not useful in these treatment profiles. Quite informative and very easy to understand. Medscape clearly was supported by Amarin in doing this but it was an enjoyable learning process and I think they will get many more physicians on board with this sort of teaching moment. Let's see what happens next after today's events.
Just look up the story in 1981 about the article linking Pancreatic Cancer to drinking coffee. It created quite a stir (no pun intended!). And of course it turns out that it was erroneous due to bias in selection of patients.
They want to re-appoint Joe as CEO plus the usual directors. They also want to raise the compensation for them (duh!) but they also want to raise the limits on borrowing which is a little disconcerting.